US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
Dec 18 (Reuters) - Checkpoint Therapeutics CKPT.O said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say